International Journal of Radiation Oncology * Biology * Physics
Volume 74, Issue 1 , Pages 1-8, 1 May 2009

Intensity-Modulated Radiotherapy Reduces Radiation-Induced Morbidity and Improves Health-Related Quality of Life: Results of a Nonrandomized Prospective Study Using a Standardized Follow-Up Program

  • Marije R. Vergeer, M.D.

      Affiliations

    • Department of Radiation Oncology, VU University Medical Center, Amsterdam, the Netherlands
    • Corresponding Author InformationReprint requests to: Marije R. Vergeer, M.D., Department of Radiation Oncology, University Hospital VU University, PO Box 7057, 1007 MB Amsterdam, The Netherlands. Tel: (+31) 20-4440413; Fax: (+31) 20-4440410l
  • ,
  • Patricia A.H. Doornaert, M.D.

      Affiliations

    • Department of Radiation Oncology, VU University Medical Center, Amsterdam, the Netherlands
  • ,
  • Derek H.F. Rietveld, M.D.

      Affiliations

    • Department of Radiation Oncology, VU University Medical Center, Amsterdam, the Netherlands
  • ,
  • C. René Leemans, M.D., Ph.D.

      Affiliations

    • Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam, the Netherlands
  • ,
  • Ben J. Slotman, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, VU University Medical Center, Amsterdam, the Netherlands
  • ,
  • Johannes A. Langendijk, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands

Received 17 March 2008; received in revised form 13 June 2008; accepted 28 July 2008. published online 25 December 2008.

Purpose

The purpose of this study was to compare intensity-modulated radiation therapy (IMRT) and three-dimensional conventional radiotherapy (3D-CRT) with regard to patient-rated xerostomia, Radiation Therapy Oncology Group (RTOG) acute and late xerostomia and health-related quality of life (HRQoL) among patients with head and neck squamous cell carcinoma (HNSCC).

Methods and Materials

Included were 241 patients with HNSCC treated with bilateral irradiation ± chemotherapy. Since 2000, all patients treated with HNSCC were included in a program, which prospectively assessed acute and late morbidity according to the RTOG and HRQoL on a routine basis at regular intervals. Before October 2004, all patients were treated with 3D-CRT (N = 150). After clinical implementation in October 2004, 91 patients received IMRT. In this study, the differences regarding RTOG toxicity, xerostomia, and other items of HRQoL were analyzed.

Results

The use of IMRT resulted in a significant reduction of the mean dose of the parotid glands (27 Gy vs. 43 Gy (p < 0.001). During radiation, Grade 2 RTOG xerostomia was significantly less with IMRT than with 3D-CRT. At 6 months, the prevalence of patient-rated moderate to severe xerostomia and Grade 2 or higher RTOG xerostomia was significantly lower after IMRT versus 3D-CRT. Treatment with IMRT also had a positive effect on several general and head and neck cancer–specific HRQoL dimensions.

Conclusions

IMRT results in a significant reduction of patient- and observer-rated xerostomia, as well as other head and neck symptoms, compared with standard 3D-CRT. These differences translate into a significant improvement of the more general dimensions of HRQoL.

IMRT, Xerostomia, Quality of life

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Presented in part at the European Society for Therapeutic Radiology and Oncology International Meeting on innovative approaches in head and neck oncology, Barcelona, Spain, February 22–24, 2007 (oral presentation); the First World Congress of the International Academy of Oral Oncology, Amsterdam, the Netherlands, May 17–20, 2007 (oral presentation); and the American Society for Therapeutic Radiology and Oncology 49th Annual Meeting, Los Angeles, November 27–December 01, 2007 (poster presentation).

 Conflict of interest: none.

PII: S0360-3016(08)03311-7

doi:10.1016/j.ijrobp.2008.07.059

International Journal of Radiation Oncology * Biology * Physics
Volume 74, Issue 1 , Pages 1-8, 1 May 2009